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Abstract Introduction: As the role of biomarkers is increasing in Alzheimer’s disease (AD) clinical trials, it is
critical to use a comprehensive temporal biomarker profile that reflects both baseline and longitudinal
assessments to establish a more precise association between the change in biomarkers and change in
cognition. Because age of onset of dementia symptoms is highly predictable, and there are relatively
few age-related comorbidities, the Dominantly Inherited Alzheimer Network autosomal dominant
AD population affords a unique opportunity to investigate these relationships in a well-
characterized population.
Methods: A novel joint statistical model was used to simultaneously evaluate how a comprehensive
AD biomarker profile predicts change in cognition using amyloid positron emission tomography
(PET), CSF Ab42, CSF total tau and Ptau181, cortical metabolism using [F-18]
fluorodeoxyglucose–PET, and hippocampal volume from participants enrolled in the Dominantly In-
herited Alzheimer Network (n 5 262) with mean (SD) duration of follow-up of 2.7 (1.2) years.
Results: Baseline amyloid PET levels and CSF biomarkers were associated with change in cognition
in contrast to the rate of change of brain metabolism and hippocampal volume, which predicted
change in cognition.
Conclusions: This study suggests that the baseline value of amyloid PET and CSF Ab42 measures
may be useful for screening participants for AD trials; however, brain hippocampus atrophy and hy-
pometabolism are only useful as repeated longitudinal assessments for tracking cognition and disease
progression. This suggests that measures of amyloid plaques predict future cognitive decline, but only
longitudinal measures of neurodegeneration correlate with cognitive decline. The novel statistical
model used in this study can be easily applied to any pair of outcomes and has potential to be widely
used by the AD research community.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
Keywords: Joint model; Biomarker; Cognition; Dominantly Inherited Alzheimer Network; Two-stage method
G.W., B.A.G., T.L.S.B., J.C.M., and C.X report no disclosures. E.M.M.
serves on the Elli Lilly-Scientific advisory board and the UpToDate advisory
board. J.H. serves as a consultant to Biogen and Lundbeck. A.M.F. serves on
the Roche Diagnostics advisory board and the Genentech advisory board,
and a consultant to Araclon/Grifols and AbbVie. R.J.B. serves as a speaker
for Janssen, Roche, and Pfizer and serves on the advisory board of Pfizer and
Merck, and serves as a consultant to Eisai.
*Corresponding author. Tel.: 1314 362-8889; Fax: 1314 362-2693.
E-mail address: guoqiao@wustl.edu
https://doi.org/10.1016/j.trci.2018.10.009
2352-8737/ 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Alzheimer’s & Dementia: Translational Research & Clinical Interventions 4 (2018) 669-676
Downloaded for Anonymous User (n/a) at Washington University School of Medicine from ClinicalKey.com by Elsevier on January 03, 2019.
For personal use only. No other uses without permission. Copyright ©2019. Elsevier Inc. All rights reserved.
1. Background
With the increase of presymptomatic Alzheimer disease
(AD) trials comes the need to improve methods for predict-
ing the relatively small decline in cognition expected over a
reasonable period. With the increase in biomarkers available
for routine use, there is a greater need to use AD biomarkers
for enrollment, interim analysis, and/or as the primary
outcome at the earliest stage of the disease. For example,
the A4 trial [1] used evidence of amyloid accumulation on
an initial positron emission tomography (PET) scan to select
trial participants, whereas the Dominantly Inherited Alz-
heimer Network-Trial Unit (DIAN-TU) [2] and the Alz-
heimer’s Prevention Initiative [3] trials used biomarkers
for an interim analysis to determine whether the trial should
end early for futility. The assumption is that such biomarker
information ultimately relates to cognitive outcomes. There-
fore, understanding the association between AD biomarkers
and early cognitive changes is critical to validate the legiti-
macy of using biomarkers as the primary outcome in preven-
tion trials.
Traditionally, the association between biomarkers and
cognition has been investigated in three ways: (1) using
biomarker values from the baseline assessment to estimate
the association with the baseline cognitive performance
and/or to predict the change in cognition [4–6]; (2) using
longitudinal biomarker values to estimate the correlation
in rates of change between biomarkers and cognition [7];
and (3) using a “two-stage” method to obtain the rate of
change in biomarkers at the first stage and then use it as a co-
variate to estimate how it predicts the change in cognition at
the second stage [8–10]. However, no studies have
simultaneously used both the baseline and longitudinal
biomarkers in a single model to predict the change in
cognition. Using both predictors in one model offers
several advantages: (1) it estimates the significance of both
the baseline and longitudinal biomarkers to predict
cognition change simultaneously; (2) provides a
comparison of which predictor is relatively more
informative; and (3) leads to more accurate estimation
because both predictors are adjusted for each other in the
same model and each individual serves as its own control
(eliminating potential confounders such as age and disease
stage). The objective of this study is to evaluate the utility
of simultaneously using the baseline value and the
longitudinal change in biomarkers to predict cognitive
decline in dominantly inherited Alzheimer’s disease in
which presence of a disease-causingmutation will invariably
lead to dementia.
2. Methods
2.1. Study design and participants
The Dominantly Inherited Alzheimer Network (DIAN)
study is a longitudinal, multinational, observational study
enrolling participants with at least 50% risk of inheriting a
disease-causing, autosomal dominant AD (ADAD) mutation
from families with a confirmed genetic mutation in one of
three genes: PSEN1, PSEN2, or APP. The presence or
absence of an ADAD mutation was determined using
PCR-based amplification of the appropriate exon followed
by Sanger sequencing. Participants with confirmed muta-
tions are referred to as mutation carriers (MCs); otherwise,
they are referred to as mutation noncarriers (NMCs). Partic-
ipants underwent clinical assessments, cognitive testing,
neuroimaging, and CSF assessments at each visit [11,12].
Participants from families that carry the APP E693G
(Dutch) mutation were excluded from the analyses
because of previous evidence of little neuritic plaque and
neurofibrillary tangle pathology [13].
2.2. Clinical and neuropsychological assessments
The Clinical Dementia Rating (CDR) Scale was used to
define dementia stage as cognitively normal (CDR 5 0),
very mild dementia (CDR 5 0.5), mild dementia
(CDR 5 1), and moderate dementia (CDR 5 2) [14]. Neu-
ropsychological tests assessing language, memory, atten-
tion, executive function, visuospatial function, and general
cognitive ability were conducted at each visit [15]. Similar
to previous studies [2,16], a composite z-score was
calculated using measures of episodic memory (delayed
recall of the DIAN 16 word-list learning test and delayed
paragraph recall from the Wechsler Memory Scale-
Revised Logical Memory Test), complex attention and pro-
cessing speed (Wechsler Adult Intelligence Scale Digit
Symbol Substitution Test), and a general cognitive screen
(Mini–Mental State Examination). The composite score
covered the major cognitive domains and reflected early
cognitive changes in the preclinical stages of ADAD [17].
2.3. Imaging acquisition and process
Magnetic resonance imaging (MRI) scans were obtained
using 3 Tesla volumetric T1-weighted MRI scanners
following the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) protocol (http://adni.loni.usc.edu/methods/docu
ments/mri-protocols/) and processed through FreeSurfer,
version 5.3 (Martinos Center, Boston, MA), as previously
described [18]. The T1-weighted images were used for mea-
surements of hippocampal volumes adjusted for total intra-
cranial volumes using a regression approach, and for
measurements of cortical volumes and ventricular volumes.
b-Amyloid (Ab) imaging with PET was acquired be-
tween 40 and 70 minutes after injection of [C-11] Pittsburgh
compound B (PiB). A standard uptake value ratio was used
to determine levels of Ab deposition for each region of inter-
est derived using FreeSurfer. Metabolic imaging with [F-18]
fluorodeoxyglucose–PET (FDG PET) was performed with a
3D dynamic acquisition starting 30 minutes after a bolus in-
jection of approximately 5 mCi of FDG and lasting 30 mi-
nutes. The mean cortical standard uptake value ratio was
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calculated from regions within the prefrontal cortex, precu-
neus, and temporal cortex as previously described [19].
2.4. CSF biomarker assays
CSF was collected in accordance with ADNI protocols.
Briefly,w15 mL of CSF was collected at 8:00 am following
overnight fasting in polypropylene tubes and was immedi-
ately frozen on dry ice. Frozen samples were shipped to
the DIAN Biomarker Core, thawed, aliquoted (0.5 ml),
flash-frozen, and stored at 284C until analysis.
All assays were performed on aliquots of the same CSF
samples. Ab42, total tau, and Ptau were measured with the
corresponding Elecsys immunoassays on the Elecsys cobas
e 601 analyzer in the laboratory of Leslie M. Shaw in the
ADNI Biomarker Core at the University of Pennsylvania as
previously described [20,21]. The Elecsys immunoassays
are electrochemiluminescence immunoassays employing a
quantitative sandwich principle. A single lot of
immunoassay reagents for each analyte was used to
measure all samples to avoid drift in the longitudinal
measures [22].
2.5. Statistical analyses
We used the concept of joint modeling similar to those
that were widely used to model longitudinal data and sur-
vival data [23,24] and developed a novel joint model of
two general linear mixed-effects (LME) models to simulta-
neously evaluate how the baseline value and the rate of
change (slope) of each biomarker predict decline in cogni-
tion. The joint model consisted of two LME submodels
and estimated them simultaneously—specifically, a
biomarker LME submodel, which included a random inter-
cept for family cluster, random intercepts and random slopes
for each individual, and fixed effect of time (years in study),
and a cognition LME submodel, which included a random
intercept for family cluster, random intercepts and random
slopes for each individual, the two-way interaction between
time and the individual biomarker random intercept, and the
two-way interaction between time and the individual
biomarker random slope. For sensitivity analysis, other co-
variates that were considered potentially associated with
cognitive outcomes such as gender, education, baseline
age, and apolipoprotein E (APOE) status were also included.
Random intercepts for each family-membership cluster were
used to account for the within-family cluster correlation.
Thus, the joint LME model simultaneously estimates the
intercept and the slope of the biomarker, the change in cogni-
tion predicted by the baseline biomarker, the change in
cognition predicted by the biomarker slope, and the change
in cognition not predicted by either the biomarker baseline
or slope. Different residual variances and different unstruc-
tured covariance matrices for random effects were assumed
for biomarkers and cognition. The joint model was estimated
using maximum likelihood and connected the same individ-
ual’s biomarker and cognition data together, thus controlling
for any potential confounders. The model was capable of
handling unevenly spaced and unbalanced biomarker and
cognition data as well as missing data [25] and thus did
not require each individual to have the same amount of
biomarker and cognition data. We applied the same analyses
separately to NMCs andMCs.We then within theMC cohort
conducted follow-up analyses separately on asymptomatic
mutation carriers (aMCs; baseline CDR 5 0) and on symp-
tomatic mutation carriers (sMCs; baseline CDR .0). All
models were implemented using proc nlmixed/SAS (SAS
Institute Inc., Cary, NC) [23], and their initial values were
estimated by applying LME separately to each outcome us-
ing proc mixed (SAS Institute Inc.). To avoid nonconvergent
problems due to dramatic differences in biomarker measure-
ment scales and the cognitive composite (z-score) [26], CSF
total tau, CSF Ab42, CSF Ptau, and MRI hippocampal vol-
umes were standardized to z-scores with mean 0 and SD 1.




We analyzed 293 MCs and 188 NMCs from the DIAN
cohort (Table 1). Of the MCs, 225 (76.8%) had PSEN1, 22
(7.5%) PSEN2, and 46 (15.7%) APP mutations. Among
the 293 MCs, 186 (63.5%) were asymptomatic (CDR 0) at
baseline.
3.2. Cognition rate of change predicted by the biomarker
The cognition rates of change predicted by the biomarker
baseline and biomarker slope in the MCs are presented in
Table 2. The estimated effect size of the predictability and
the comparison between the baseline and the rate of change
are summarized in Fig. 1. Overall, the baseline value for CSF
total tau, CSF Ptau, CSF Ab42, and PiB PET is a better pre-
dictor of the cognitive decline than their respective longitu-
dinal change, whereas the longitudinal change is a better
predictor for MRI hippocampus volume, FDG PET
(Fig. 1). MRI hippocampus volume is the only biomarker
whose baseline and rate of change are both significantly
associated with the change in cognition.
The effect size of baseline PiB was such that a 1-unit in-
crease in amyloid-PiB led to 0.15 z-score greater annual
decline in cognitive composite score. Furthermore, after ac-
counting for the change associated with both the baseline
and the change in PiB PET, the remaining change in cogni-
tion was positive (Table 2) suggesting that below a certain
threshold of PiB, (estimated to be 1.3 using the same model)
the cognitive change is minimal or slightly positive. Because
we have found the precuneus to be an area of very early PiB-
PET increase [27], we repeated the analyses limiting it to the
precuneus. We found not only was the baseline value more
informative than the rate of change but the baseline also
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became significant [20.26 (0.06), P , .0001 for PiB base-
line; 0.61 (0.62), P 5 .32 for PiB rate of change].
For all CSF biomarkers, only the baseline value was
related to change in cognition. This is not surprising for total
tau and Ptau because their rates of change were not signifi-
cant. The fact that the rate of change of CSF Ab42 was sig-
nificant but not related to change in cognition suggests that
the rate of change of CSF Ab42 was much earlier than that
of cognition.
For global FDG PET, the longitudinal change predicted
change in cognition, but not the baseline (Table 2). Specif-
ically, the annual rate of change in FDG PET was 20.009,
leading to a 0.03 z-score decline in cognitive composite
score. Both the baseline value and the change in hippocam-
pal volume predicted cognitive change; however, the weight
on the longitudinal predictor was noticeably larger (0.99)
than the baseline value (0.06) suggesting relatively greater
importance. Participants with 1 SD larger in the baseline
MRI hippocampal volumes would correspond to 0.06
z-score reduction in the cognition decline, and their 0.11
z-score annual decrease in MRI hippocampal volumes
would lead to about 0.11 z-score increase in the cognitive
decline. Additional analysis using MRI cortical volumes
and MRI total ventricle volumes showed that only the longi-
tudinal change in MRI cortical volumes predicted change in
cognition (data not shown). Sensitivity analyses indicated
that including gender, education, baseline age, and APOE
status in the joint model yielded similar results for the
biomarker predictability of the rate of change in cognition.
As expected, because the NMCs in DIAN are a relatively
young cohort, their biomarkers and cognition did not decline
during the follow-up, and thus no association between the
biomarker profile and cognition decline was observed
(Supplemental Table 1).
The results for asymptomatic MCs were similar to those
for the combined MC group, although some of them were
not significant because of the smaller sample size and the
decrease in the magnitude of change (Supplemental
Table 2). For symptomatic MCs, the results generally
demonstrated consistent patterns, although the weight of
the predictability in the rate of change for FDG PET largely
increases (Supplemental Table 3). In addition, the rate of
change of CSF Ptau became negative and significantly asso-
ciated with the cognitive rate of change (Supplemental
Table 3).
4. Discussion
Using the DIAN longitudinal study and a novel mixed-
effects model, we simultaneously evaluated/tested the predict-
ability of the biomarker baseline and the biomarker change
(slope) on the cognitive change and showed that for different
biomarkers, the predictability of the slope vs. baseline values
differed. Specifically, change in cognitionwas better predicted
by baseline rather than change in PiB PET and CSF bio-
markers, whereas the rate of change for the remaining bio-
markers (FDG PET, hippocampal volume) was the better
predictor of the cognitive change.To our knowledge, this study
represents the first attempt to use the whole biomarker profile
(baseline and change) to establish the association between all
major AD biomarkers and cognition across the spectrum of
disease from preclinical to cognitively impaired. A clear
advantage of using the whole biomarker profile is that the
model allows comparison of the predictability between the
biomarker baseline and the biomarker change.
Consistent with previous reports [4–6], we found that
higher cerebral amyloid deposition at baseline predicted
longitudinal cognitive decline; however, the individual rate
of change in amyloid did not. Xiong et al. [7] previously
evaluated the correlation between the change in amyloid
deposition and the change in cognition in sporadic AD and
concluded that the correlation was not significant, which is
indirectly validated by our result in that the former does
not predict the latter. For both cerebral amyloid deposition
and CSF Ab42, the baseline value is more informative than
the longitudinal change in predicting the cognitive decline.
This result further supports using baseline amyloid burden
such as PiB PET as an important biomarker inclusion for
Table 1
Baseline characteristics of MCs, aMCs, sMCs, and NMCs
Characteristics MC (N 5 293) aMC (N 5 186) sMC (N 5 107) NMC (N 5 188)
Female, N (%) 161 (55.0) 106 (57.0) 55 (51.4) 112 (60.0)
Age (y), mean (SD) 38.57 (11.04) 34.01 (8.81) 46.48 (10.04) 38.29 (11.59)
Education (y), mean (SD) 14.28 (3.02) 14.78 (2.86) 13.42 (3.1) 14.73 (2.93)
Apolipoprotein E ε4 carrier, N (%) 88 (30.0) 54 (29.0) 34 (31.8) 59 (31.4)
CSF Ab42 (pg/mL), mean (SD) 892.97 (576.52) 1069.9 (601.2) 533.82 (287.24) 1248.82 (440.18)
CSF total tau (pg/mL), mean (SD) 288.58 (164.47) 228.77 (102.37) 409.97 (197.55) 173.26 (58.91)
CSF Ptau181 (pg/mL), mean (SD) 30.7 (23.22) 21.44 (13.65) 49.49 (27.09) 14.28 (5.15)
Amyloid PIB PET global SUVR, mean (SD) 1.97 (1.03) 1.65 (0.77) 2.76 (1.16) 1.06 (0.15)
FDG PET global SUVR, mean (SD) 1.68 (0.17) 1.73 (0.14) 1.58 (0.19) 1.71 (0.14)
Hippocampal volume (mm3), mean (SD) 4194.44 (642.22) 4439.5 (484.65) 3709.84 (642.37) 4398.93 (404.26)
DIAN cognitive composite, mean (SD) -0.61 (1.05) -0.06 (0.61) -1.68 (0.89) -0.03 (0.62)
Abbreviations: DIAN, Dominantly Inherited Alzheimer Network; MC, mutation carrier; aMC, asymptomatic MC; sMC symptomatic MC; NMC, mutation
noncarrier; SUVR, standard uptake value ratio.
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secondary prevention trials in AD [1,3], and as a principle
component of the newly proposed AD diagnostic criteria
[28,29]. Also it has been reported that low baseline CSF
Ab42 leads to significant cognitive decline [7,30], this
pattern was consistent in our results. In addition, the rate
of change in CSF Ab42 did not significantly predict the
rate of cognitive decline, which is similar to the lack of
correlation in previous reports [7]. This finding reveals that
at the very early disease stage when the CSF Ab42 decline
is most prominent, cognition actually does not decline as
fast as when the CSF Ab42 decline is relatively moderate
or plateaued later in the disease.
Adecline in hippocampal volumehas beendemonstrated to
be associated with cognitive decline [7,8], but the results with
baseline hippocampal volume are inconsistent [7,8]. These
differences could be attributed to the different study cohorts
(e.g., age of onset, comorbid pathologies). Our results
indicate that in this younger population both the baseline and
the rate of change in hippocampal volumes predict cognitive
decline, which verifies previous results using different
cognitive tests [8]. Although other studies have shown that
both the baseline and the change in FDG-PETwere associated
with cognitive decline [9], we found that only the change
significantly predicted the cognitive decline. The discrepancy
might be due to the study cohorts (sporadicADvsADAD), the
sample size, or the analytical methods. Again, an important
advantage of our analysis is that it takes into account, simulta-
neously, the baseline (accumulation of pathology at a specific
time) and the change (ongoing pathological dynamics) to bet-
ter account for the total burden of pathology in a diseasewith a
prolonged time course.
Although our study had many strengths, there are also
several limitations that warrant mention. First, our analyses
are basedonanADADcohort, andour findingsmaynot extend
to the more common sporadic AD where the age of onset is
much older and additional pathologies less common in
ADAD (e.g., TDP-43, cerebrovascular disease) might influ-
ence the associations identified here. Although these merit
direct investigation, two recently published articles using a
data-driven, event-based modeling technique identified a
similar biomarker/cognition profile between ADAD and spo-
radic AD (initial change in Ab, followed by CSF measures
of tau/ptau, brain atrophy, and then cognitive decline)
[31,32], thus providing evidences that the association
between the biomarker longitudinal change and cognitive
decline might be similar in sporadic AD. Ongoing studies in
the Alzheimer Disease Neuroimaging Initiative and DIAN
will provide the opportunity to directly compare cohorts that
are followed with very similar procedures [33]. In addition,
although this ADAD cohort is evenly represented by gender,
ethnical minority groups such as African Americans and His-
panics in US and Asians worldwide are underrepresented,
leading to potential selection bias and warranting caution
when generalizing our study results. It is possible that subtle
genetic differences between races might affect the expression
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recent work in sporadic AD has suggested that levels of CSF
biomarkers may differ between African Americans and non-
Hispanic white Americans [34]. Unfortunately, our current
numbers of non-Hispanic whites are relatively low limiting
our ability to explore these factors. Similarly, specific
geographic and socioeconomic differences could contribute
to differences in cognitive reserve resulting in differences in
cognitive change at similar biomarker levels. Expansion of
the DIAN cohort as well as the large kindred from Colombia
[35] should providegood opportunities to further explore these
potentially important contributors. Future research should also
directly analyze a sporadic AD cohort and include subgroup
analyses for age and ethnic groups to evaluate whether or not
our findings replicate. Second, our cognitive composite score
is composed of tests that are different from those used in pre-
vious studies [4–9]; therefore, caution is needed to interpret
the discrepancies in various findings, which may be due to
the relative sensitivity of various cognitive tests. Third, there
are challenges to interpret the findings when using z-
scores—primarily, the loss of meaningfulness of the raw
score and its standard deviation, magnifying small changes,
not reflecting the reality ofmemorydeclines [36]. Similar anal-
ysis may also be done directly for each individual cognitive/
clinical test on their original scales to avoid the interpretation
difficulty of using z-scores. Fourth, we assumed that both the
cognitive decline and the biomarker change are linear.
Although this is valid in our study cohort at the individual level
given the relatively short follow-up, such changesmaybecome
nonlinear as the follow-up period increases. Exploration of
nonlinear longitudinal change in both biomarkers and cogni-
tive tests may provide more accurate evaluation of the associ-
ations among them but requires more complicatedmodels and
computation times. A further challenge for these future re-
searches is to obtain an appropriate data set, which has
adequate follow-up to demonstrate potential nonlinear change
and provides sufficient sample size for subgroup analysis.
Importantly, the comprehensive protocol followed inDIANal-
lows for a rich biomarker and clinical characterization of par-
ticipants at multiple stages in the disease process. Ongoing
work to implement novel cognitive test paradigms in DIAN
[37] coupled with the extensive biomarkers collected will
allow us to explore possible nonlinear cognitive patterns
such as practice effects.
Our findings are based on a novel method using the whole
biomarker profile (baseline1 change) simultaneously and in
most cases are consistent with previous results. The method
is able to establish the association or lack of between the
whole biomarker profile and cognitive decline. It also pro-
vides a comparison of the predictability, which helps deter-
mine which biomarker to use to identify the “right” trial
cohort at enrollment and which biomarker to use at the
interim analysis to determine whether a drug is hitting the
target in AD clinical trials. Furthermore, the method can
be applied to any pair of longitudinal outcomes (e.g., PiB
PET and CSF Ab42) to explore their association or to eval-
uate their order of change.
Fig. 1. The relationship between the baseline and the slope in biomarkers to predict the rate of change in cognition. ES: effect size (mean/SD) of the change in
cognition associated with 1-unit (or SD) change in the baseline or the slope. PiB: PiB cortical mean; FDG: total cortical mean. MRI: average hippocampus
volume; Ab42: CSF Elecsys Ab42; tau: CSF Elecsys total tau; Ptau: CSF Elecsys ptau. Abbreviations: FDG, [F-18] fluorodeoxyglucose; MRI, magnetic reso-
nance imaging; PET, positron emission tomography; PiB, [C-11] Pittsburgh compound B.
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RESEARCH IN CONTEXT
1. Systematic review: We reviewed the existing litera-
ture on establishing the association between bio-
markers and cognition. Most studies investigated
either only baseline biomarker levels or longitudinal
changes in biomarkers. For those studies that used
both, they typically used a “two-stage” analytic
method, which can lead to biased or inaccurate esti-
mation.
2. Interpretation: An informative comparison between
the predictability of the baseline and the rate of
change of the biomarkers for cognitive change facil-
itates the use of biomarkers in Alzheimer’s disease
(AD) clinical trials.
3. Future directions: Repeated biomarker assessments
are valuable for studies focused on cognitive changes
in AD populations. Joint models that incorporate
both baseline and longitudinal measures of AD bio-
markers are likely to have more accurate predictive
power than either method alone and may be
extremely useful for primary and secondary preven-
tion trials in AD.
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